Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Prestige Buys Insight, Quarterly Earnings For MJN And Colgate, Bio-Recovery Warned On Claims

This article was originally published in The Tan Sheet

Executive Summary

Prestige acquires Insight Pharmaceuticals; Product relaunches boost Novartis’ consumer sales; Colgate’s N.A. sales inch up; Mead Johnson sales up 7%; and Bio-Recovery makes drug claims.

You may also be interested in...



Prestige Brands Prepares To Weather Retailers' Inventory Storm

The firm's sales of BC, Goody's, Monistat and other consumer health care brands grow 4.3% in North America and 17.8% internationally in its latest quarter. CEO Ron Lombardi says Prestige Brands expects lower volume orders from retailers during the current quarter and early 2017.

Prestige Brands Prepares To Weather Retailers' Inventory Storm

The firm's sales of BC, Goody's, Monistat and other consumer health care brands grow 4.3% in North America and 17.8% internationally in its latest quarter. CEO Ron Lombardi says Prestige Brands expects lower volume orders from retailers during the current quarter and early 2017.

Prestige Brands Invests $111m To Boost Advertising From Market Research

Prestige Brands supports leading brands including Monistat and Dramamine with promotional campaigns stemming from research into consumer preferences, says sales and marketing head Timothy Connors. With $111m ad spend, it aims to become a “preeminent marketing and sales” firm.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel